Point of Care Lipid Test Market Size to Touch USD 453.90 Mn by 2033

The global point of care lipid test market size was estimated at USD 294.70 million in 2023, growing at a CAGR of 4.41% from 2024 to 2033. The Point of Care (POC) lipid test market is a segment of the healthcare industry focused on devices and testing methods that allow for quick and convenient assessment of lipid levels in patients. These tests are designed for use at the patient’s bedside or in outpatient settings, offering immediate results to aid in diagnosis and monitoring of conditions such as hyperlipidemia and cardiovascular diseases. With the rising prevalence of lifestyle-related diseases, such as obesity and diabetes, the demand for POC lipid testing has grown. These tests provide healthcare professionals with timely data to make informed decisions about patient care, particularly in managing heart disease risk.

Point of Care Lipid Test Market Size 2024 to 2033

Key Points

North America held a significant share of in the point of care lipid test market in 2023 with 38.6%.
Asia Pacific is anticipated to experience the highest growth in the upcoming years.
By product, the consumables type segment has accounted market share of 57% in 2023.
By application, in 2023, the endogenous hyperlipidemia segment dominated the market with 46% revenue share.
By end use, the diagnostic centers segment has held largest market share of 56% in 2023.

Growth Factors

Several factors contribute to the growth of the POC lipid test market:

Increasing Prevalence of Cardiovascular Diseases: Cardiovascular diseases (CVDs) remain a leading cause of death worldwide. Early detection and management of lipid disorders can help mitigate the risk of CVDs, fueling demand for POC lipid tests.
Technological Advancements: Innovations in POC testing technology have improved the accuracy and reliability of lipid tests, making them more appealing to healthcare providers.
Growing Awareness of Preventative Healthcare: There is a rising emphasis on preventive healthcare, leading to more frequent testing for lipid levels to manage potential risks before they lead to serious health problems.
Convenience and Quick Results: POC lipid tests provide immediate results, allowing healthcare professionals to make quick decisions regarding patient treatment plans.
Increasing Geriatric Population: As the global population ages, there is a growing need for regular monitoring of lipid levels among older adults, who are more prone to cardiovascular issues.

Region Insights

The market for POC lipid tests varies across different regions:

North America: North America is a leading region in the POC lipid test market, driven by a high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and increased awareness of preventative healthcare.
Europe: Europe is also a significant market for POC lipid tests, with strong healthcare systems and a high adoption rate of new medical technologies.
Asia-Pacific: This region is expected to witness substantial growth due to rising healthcare expenditure, increasing awareness of preventative care, and a growing population with a high incidence of lifestyle-related diseases.
Latin America and Middle East & Africa: These regions may see moderate growth due to increasing healthcare investment and the adoption of advanced medical technologies, but challenges such as limited healthcare infrastructure may impede rapid expansion.

Point of Care Lipid Test Market Scope

Report Coverage	Details
Global Market Size in 2023	USD 294.70 Million
Global Market Size in 2024	USD 307.71 Million
Global Market Size by 2033	USD 453.90 Million
Growth Rate from 2024 to 2033	CAGR of 4.41%
Largest Market	North America
Base Year	2023
Forecast Period	2024 to 2033
Segments Covered	By Product Type, By Application, and By End-user
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Point of Care Lipid Test Market Dynamics

Drivers

Demand for Preventive Care: As patients and healthcare providers focus more on prevention, routine lipid testing has become a critical part of medical check-ups, boosting demand for POC lipid tests.
Homecare and Telehealth Expansion: The increase in homecare and telehealth options has expanded the application of POC lipid tests, as patients can monitor their health at home.
Government Initiatives: Many governments have launched campaigns to raise awareness about cardiovascular health and the importance of monitoring cholesterol levels, driving the market’s growth.
Rising Healthcare Costs: POC tests provide a cost-effective alternative to traditional laboratory tests, making them an attractive option for healthcare providers looking to reduce costs.

Opportunities

Emerging Markets: There is significant potential for market growth in emerging markets, where the prevalence of lifestyle-related diseases is increasing.
Technological Innovation: Continued advancements in POC testing technology, such as improved accuracy and user-friendly designs, offer opportunities for market expansion.
Partnerships and Collaborations: Collaboration between medical device companies and healthcare providers can lead to new opportunities for POC lipid testing adoption.
Regulatory Support: Favorable regulatory environments can open up new opportunities for manufacturers to develop and market POC lipid tests.

Challenges

Regulatory Hurdles: POC lipid tests must adhere to strict regulations to ensure safety and efficacy, which can slow down product development and market entry.
Cost Barriers: While POC tests can be cost-effective in the long run, the initial cost of purchasing equipment can be a barrier for some healthcare providers.
Limited Reimbursement: In some regions, reimbursement for POC lipid testing may be limited, which can hinder market growth.
Competition from Traditional Labs: Traditional laboratories still dominate the market for lipid testing, presenting a challenge to the adoption of POC lipid tests.

Recent Developments

In October 2022 Genes2Me Pvt. Ltd launched Rapi-Q- Point of Care RT PCR solution for human papillomavirus (HPV) and tuberculosis. The device is easy to use and gives faster results in less than 45 minutes. This CE-IVD-marked POC solution delivers superior performance, high sensitivity, and stable detection.
In March 2022, Visby Medical announced that it received funding of USD 25.5 million from the U.S. Biomedical Advanced Research and Development Authority to develop a rapid flu-COVID-19 PCR test for home use. At present, the test is in the under-developing phase, and the design is ready as a PCR device that can detect COVID-19, influenza A, and B from a single sample.
In March 2022, Canada-based Company BioLytical Laboratories Inc. received a CE marking for the iStatis COVID-19 Antigen Home Test.
In May 2022, Qiagen Inc. launched the NeuMoDxHSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 (HSV-1) DNA and herpes simplex virus type 2 (HSV-2) with approval from the European Commission. The emergence of this assay is allowing the company to expand its product portfolio in laboratory testing, which ultimately helps the market grow owing to the innovative tests.
In March 2022, Mindray launched the BC-700 Series, a hematology analyzer series that assists in both blood count and erythrocyte sedimentation rate tests.